Gilteritinib (Xospata®) accepted for use within NHS Scotland

Gilteritinib oral tablet is approved as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia with a FLT3 mutation.

Source:

Scottish Medicines Consortium